Review Evaluates Long-Lived Plasma Cells as Therapeutic Targets in Rheumatic and Autoimmune Diseases

A structured narrative review suggests that while persistent autoreactive long-lived plasma cells represent a treatment-relevant disease module, tissue, clonal, and longitudinal evidence are required to guide targeted interventions.

Researchers published a structured narrative review in Autoimmunity Reviews focusing on the biology, evidence, and therapeutic opportunities of long-lived plasma cells (LLPCs) in rheumatic and selected antibody-mediated autoimmune diseases.

The authors noted that LLPCs can survive without ongoing proliferation and maintain pathogenic antibodies, resisting conventional immunosuppression or B-cell depletion.

The review highlights that defining LLPCs remains complex as longevity is typically inferred rather than demonstrated via lineage tracing in humans, and no single surface phenotype (such as CD19 loss) serves as a definitive identifier.

Clinically relevant signals have been observed with plasma-cell-directed therapies, including proteasome inhibition, CD38 depletion, and BCMA-directed T-cell engagers or cellular therapies, although most autoimmune data remain early-phase, uncontrolled, or disease-specific.

Targeting pathogenic LLPCs without depleting the beneficial LLPCs required for durable protective immunity is a critical hurdle in autoimmune therapies.

The paper introduces a translational framework advising against treating LLPCs as universal master drivers, suggesting instead that they should be validated as disease-specific modules through tissue, clonal, and longitudinal evidence before intervention.

Alternative therapeutic strategies such as niche disruption, apoptosis or autophagy inhibition, and antigen-specific deletion remain in preclinical or conceptual stages.

Developers of CD38, BCMA, and proteasome-targeted therapeutics face the need to generate robust, controlled clinical data and tissue-specific biomarkers to validate their pipelines in refractory autoimmune indications like lupus nephritis.

The preclinical status of niche disruption and autophagy/apoptosis-inhibiting therapies indicates open, early-stage development pathways for biotechnology platforms targeting cellular adaptation mechanisms in chronic inflammation.

Translational progress of preclinical concepts like niche disruption, autophagy inhibition, and antigen-specific deletion into early-stage clinical trials.

Clinical updates and controlled data from ongoing CD38- and BCMA-targeted trials in systemic lupus erythematosus (SLE) and lupus nephritis.